Metabloq Pty Ltd (MetabloQ Pharmaceuticals) is a privately-held biotechnology company developing drugs for difficult-to-treat cancers with a primary focus on triple negative breast cancer. With partners - The Centenary Institute, The University of Sydney and CSIRO - Metabloq are undertaking a drug discovery and development program directed towards a novel target involved in cancer metabolism.
MiniFAB specialises in developing and manufacturing custom micro-engineered solutions that solve complex problems, often integrating microfluidics, polymer and hybrid materials and advanced manufacturing processes.
Minomic International Ltd is an Australian immuno-oncology company that has developed an in vitro diagnostic test for the detection of prostate cancer called MiCheck®. In clinical studies, MiCheck® has demonstrated superior specificity compared with prostate-specific antigen (PSA), which is the current standard of care.
Established in 2008, Mobius Medical is a full service, ISO 9001 certified Australian CRO, providing outstanding clinical trial management and electronic data capture (EDC) services throughout Australia.
Monash University was established in Melbourne, Australia in 1958, believing quality education and research can change the world for the better. Monash has achieved an enviable national and international reputation for research and teaching excellence in a short 50 years.
Monash Vision Group (MVG) is a Melbourne-based collaborative partnership between Monash University, Alfred Health, MiniFab and Grey Innovation. MVG's primary goal is to develop a clinically viable cortical vision prosthesis to restore vision in blind individuals. Since receiving an Australian Research Council (ARC) grant in 2010, MVG has successfully manufactured and tested a wireless, implantable system that can deliver complex electrical signals directly to the visual cortex.
movendo is an engineering consultancy active in the planning, community building and health sectors. They stand at the crossroads of technology, ecology and culture, supporting the diversity of relationships between people and encouraging their interactions with nature and the built environment for the realisation of sustainable outcomes.
For more than a century, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA.
MuPharma is a business based in Victoria, Australia that has developed various novel, ultrasound based, non-invasive devices to deliver drugs to the body that would ordinarily require injections or other highly invasive delivery means. Principal sites of application include the eye (anterior and posterior segment) and the inside of the mouth.
Murdoch University in Perth, Australia, have more than 22,000 students and 2,000 staff from across 90 different countries.
My Emergency Dr is an Australian-owned and operated 24/7 tele-emergency service that instantly puts patients, carers and clinicians in touch with a specialist emergency physician via a freely downloadable videoconferencing app.
My Sport Evolution represents Hexoskin in Australia, the only clinically validated wearable system that allows ECG cardiac monitoring with lung function and activity tracking. Hexoskin is a cost-effective and non-invasive solution for long-term (remote) patient observation & data collection.
MyOnlineClinic is the only integrative cloud based Health Tech platform that enables all Healthcare providers connectivity as a PMS (practice management software) through Telehealth using mobile technology, connected to bluetooth enabled medical devices and wearables best environment to diagnose and manage health.
NanoMed Pty Ltd is a nanobiotech company based in Sydney, Australia. Our mission is to design, develop and commercialise colloidal nanomedicines for use as cancer therapeutics and diagnostic imaging agents.
NCI is the leading national institution for high performance computing, and provides world-class high-end services to more than 4,000 Australian researchers from 31 universities, five science agencies and several medical research institutes.
The National Health and Medical Research Council (NHMRC) is Australia’s leading expert body promoting the development and maintenance of public and individual health standards.
NeuroScientific Biopharmaceuticals Ltd is an Australian public company developing novel peptide-based pharmaceutical products that target a number of neurological disorders that have high unmet medical needs.
NextMed Capital's mission is to nurture the seeds of the next generation of medical innovation. The company was founded in 2016 with the goal of becoming Australia's leading very early stage innovation and medical technology investor. NextMed Capital can invest in projects as early as the pre-clinical phase and adds significant value to its investments through leveraging the combined commercial, entrepreneurial, project management, financing, business planning and academic skills of its experienced management team.
Formed in October 2013, NIESM is a Melbourne-based Australian company that delivers clinician support tools focused around wearable technologies and an enterprise software platform to provide optimal health outcomes for patients with epilepsy. NIESM has put together a global team with world leaders in technology, clinical and business capabilities and they are committed to helping patients become seizure free.